Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Arterioscler Thromb Vasc Biol ; 32(5): 1204-10, 2012 May.
Article in English | MEDLINE | ID: mdl-22345169

ABSTRACT

OBJECTIVE: Lipoprotein lipase (LPL) is a principal enzyme in lipoprotein metabolism, tissue lipid utilization, and energy metabolism. LPL is synthesized by parenchymal cells in adipose, heart, and muscle tissues followed by secretion to extracellular sites, where lipolyic function is exerted. The catalytic activity of LPL is attained during posttranslational maturation, which involves glycosylation, folding, and subunit assembly within the endoplasmic reticulum. A lipase-chaperone, lipase maturation factor 1 (Lmf1), has recently emerged as a critical factor in this process. Previous studies demonstrated that loss-of-function mutations of Lmf1 result in diminished lipase activity and severe hypertriglyceridemia in mice and human subjects. The objective of this study is to investigate whether, beyond its role as a required factor in lipase maturation, variation in Lmf1 expression is sufficient to modulate LPL activity in vivo. METHODS AND RESULTS: To assess the effects of Lmf1 overexpression in adipose and muscle tissues, we generated aP2-Lmf1 and Mck-Lmf1 transgenic mice. Characterization of relevant tissues revealed increased LPL activity in both mouse strains. In the omental and subcutaneous adipose depots, Lmf1 overexpression was associated with increased LPL specific activity without changes in LPL mass. In contrast, increased LPL activity was due to elevated LPL protein level in heart and gonadal adipose tissue. To extend these studies to humans, we detected association between LMF1 gene variants and postheparin LPL activity in a dyslipidemic cohort. CONCLUSIONS: Our results suggest that variation in Lmf1 expression is a posttranslational determinant of LPL activity.


Subject(s)
DNA/genetics , Energy Metabolism/physiology , Gene Expression Regulation , Genetic Variation , Hypertriglyceridemia/genetics , Lipoprotein Lipase/genetics , Membrane Proteins/genetics , Adipose Tissue/metabolism , Animals , Humans , Hypertriglyceridemia/metabolism , Lipoprotein Lipase/biosynthesis , Membrane Proteins/biosynthesis , Mice , Mice, Transgenic , Muscle, Skeletal/metabolism , Myocardium/metabolism
3.
J Lipid Res ; 52(6): 1162-1169, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21447484

ABSTRACT

Lipase maturation factor 1 (Lmf1) is an endoplasmic reticulum (ER) membrane protein involved in the posttranslational folding and/or assembly of lipoprotein lipase (LPL) and hepatic lipase (HL) into active enzymes. Mutations in Lmf1 are associated with diminished LPL and HL activities ("combined lipase deficiency") and result in severe hypertriglyceridemia in mice as well as in human subjects. Here, we investigate whether endothelial lipase (EL) also requires Lmf1 to attain enzymatic activity. We demonstrate that cells harboring a (cld) loss-of-function mutation in the Lmf1 gene are unable to generate active EL, but they regain this capacity after reconstitution with the Lmf1 wild type. Furthermore, we show that cellular EL copurifies with Lmf1, indicating their physical interaction in the ER. Finally, we determined that post-heparin phospholipase activity in a patient with the LMF1(W464X) mutation is reduced by more than 95% compared with that in controls. Thus, our study indicates that EL is critically dependent on Lmf1 for its maturation in the ER and demonstrates that Lmf1 is a required factor for all three vascular lipases, LPL, HL, and EL.


Subject(s)
Endoplasmic Reticulum/metabolism , Fibroblasts/metabolism , Hypertriglyceridemia/metabolism , Lipase/metabolism , Lipoprotein Lipase/metabolism , Membrane Proteins , Animals , Chromatography, Affinity , Electroporation , Endoplasmic Reticulum/genetics , Fibroblasts/cytology , HEK293 Cells , Humans , Hypertriglyceridemia/genetics , Hypertriglyceridemia/physiopathology , Lipase/genetics , Lipoprotein Lipase/genetics , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Mutation , Plasmids , Transfection
4.
Metabolism ; 58(4): 560-7, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19303979

ABSTRACT

Apolipoprotein A5 (APOA5) is expressed primarily in the liver and modulates plasma triglyceride levels in mice and humans. Mice overexpressing APOA5 exhibit reduced plasma triglyceride levels. Because there is a tight association between plasma triglyceride concentration and traits of the metabolic syndrome, we used transgenic mice overexpressing human APOA5 to test the concept that these mice would be protected from diet-induced obesity and insulin resistance. Male and female transgenic and wild-type mice on the FVB/N genetic background were fed standard rodent chow or a diet rich in fat and sucrose for 18 weeks, during which time clinical phenotypes associated with obesity and glucose homeostasis were measured. We found that APOA5 transgenic (A5tg) mice were resistant to diet-induced changes in plasma triglyceride but not total cholesterol levels. Body weights were similar between the genotypes for females and males, although male A5tg mice showed a modest but significant increase in the relative size of inguinal fat pads. Although male A5tg mice showed a significantly increased ratio of plasma glucose to insulin, profiles of glucose clearance as evaluated after injections of glucose or insulin failed to reveal any differences between genotypes. Overall, our data showed that there was no advantage to responses to diet-induced obesity with chronic reduction of plasma triglyceride levels as mediated by overexpression of APOA5.


Subject(s)
Apolipoproteins/metabolism , Blood Glucose/metabolism , Homeostasis/genetics , Weight Gain/genetics , Animals , Apolipoprotein A-V , Apolipoproteins/genetics , Body Weight , Female , Insulin Resistance , Lipase/metabolism , Lipids/blood , Male , Mice , Mice, Transgenic
SELECTION OF CITATIONS
SEARCH DETAIL
...